TITLE

The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells

AUTHOR(S)
Ford, Anthony M.; Palmi, Chiara; Bueno, Clara; Dengli Hong; Cardus, Penny; Knight, Deborah; Cazzaniga, Giovanni; Enver, Tariq; Greaves, Mel; Hong, Dengli
PUB. DATE
April 2009
SOURCE
Journal of Clinical Investigation;Apr2009, Vol. 119 Issue 4, p826
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Chromosome translocation to generate the TEL-AML1 (also known as ETV6-RUNX1) chimeric fusion gene is a frequent and early or initiating event in childhood acute lymphoblastic leukemia (ALL). Our starting hypothesis was that the TEL-AML1 protein generates and maintains preleukemic clones and that conversion to overt disease requires secondary genetic changes, possibly in the context of abnormal immune responses. Here, we show that a murine B cell progenitor cell line expressing inducible TEL-AML1 proliferates at a slower rate than parent cells but is more resistant to further inhibition of proliferation by TGF-beta. This facilitates the competitive expansion of TEL-AML1-expressing cells in the presence of TGF-beta. Further analysis indicated that TEL-AML1 binds to a principal TGF-beta signaling target, Smad3, and compromises its ability to activate target promoters. In mice expressing a TEL-AML1 transgene, early, pre-pro-B cells were increased in number and also showed reduced sensitivity to TGF-beta-mediated inhibition of proliferation. Moreover, expression of TEL-AML1 in human cord blood progenitor cells led to the expansion of a candidate preleukemic stem cell population that had an early B lineage phenotype (CD34+CD38-CD19+) and a marked growth advantage in the presence of TGF-beta. Collectively, these data suggest a plausible mechanism by which dysregulated immune responses to infection might promote the malignant evolution of TEL-AML1-expressing preleukemic clones.
ACCESSION #
37557303

 

Related Articles

  • The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Scuto, A.; Krejci, P.; Popplewell, L.; Wu, J.; Kujawski, M.; Kowolik, C.; Xin, H.; Chen, L.; Wang, Y.; Kretzner, L.; Yu, H.; Wilcox, W. R.; Yen, Y.; Forman, S.; Jove, R. // Leukemia (08876924);Mar2011, Vol. 25 Issue 3, p538 

    IL-6 and downstream JAK-dependent signaling pathways have critical roles in the pathophysiology of multiple myeloma (MM). We investigated the effects of a novel small-molecule JAK inhibitor (AZD1480) on IL-6/JAK signal transduction and its biological consequences on the human myeloma-derived...

  • The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. Bongers, Gerold; Maussang, David; Muniz, Luciana R.; Noriega, Vanessa M.; Fraile-Ramos, Alberto; Barker, Nick; Marchesi, Federica; Thirunarayanan, Nanthakumar; Vischer, Henry F.; Lihui Qin; Mayer, Lloyd; Harpaz, Noam; Leurs, Rob; Furtado, Glaucia C.; Clevers, Hans; Tortorella, Domenico; Smit, Martine J.; Lira, Sergio A.; Qin, Lihui // Journal of Clinical Investigation;Nov2010, Vol. 120 Issue 11, p3969 

    US28 is a constitutively active chemokine receptor encoded by CMV (also referred to as human herpesvirus 5), a highly prevalent human virus that infects a broad spectrum of cells, including intestinal epithelial cells (IECs). To study the role of US28 in vivo, we created transgenic mice (VS28...

  • HIV-1 Rev-binding protein accelerates cellular uptake of iron to drive Notch-induced T cell leukemogenesis in mice. Khwaja, Shariq S.; Hudan Liu; Caili Tong; Fang Jin; Pear, Warren S.; van Deursen, Jan; Bram, Richard J.; Liu, Hudan; Tong, Caili; Jin, Fang // Journal of Clinical Investigation;Jul2010, Vol. 120 Issue 7, p2537 

    Somatic activating mutations in Notch1 contribute to the pathogenesis of T cell acute lymphoblastic lymphoma (T-ALL), but how activated Notch1 signaling exerts this oncogenic effect is not completely understood. Here we identify HIV-1 Rev-binding protein (Hrb), a component of the...

  • IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. Fisher, Daniel T.; Qing Chen; Skitzki, Joseph J.; Muhitch, Jason B.; Lei Zhou; Appenheimer, Michelle M.; Vardam, Trupti D.; Weis, Emily L.; Passanese, Jessica; Wan-Chao Wang; Gollnick, Sandra O.; Dewhirst, Mark W.; Rose-John, Stefan; Repasky, Elizabeth A.; Baumann, Heinz; Evans, Sharon S.; Chen, Qing; Zhou, Lei; Wang, Wan-Chao // Journal of Clinical Investigation;Oct2011, Vol. 121 Issue 10, p3846 

    Immune cells are key regulators of neoplastic progression, which is often mediated through their release of cytokines. Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and survival of neoplastic cells. However, whether these cytokines also have a role in...

  • SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. Evel-Kabler, Kevin; Song, Xiao-Tong; Aldrich, Melissa; Huang, Xue F.; Chen, Si-Yi // Journal of Clinical Investigation;Jan2006, Vol. 116 Issue 1, p90 

    DC-based tumor vaccine research has largely focused on enhancing DC maturation/costimulation and antigen presentation in order to break tolerance against self tumor-associated antigens. DC immunization can activate autoreactive T cells but rarely causes autoimmune pathologies, indicating that...

  • FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. Kamagate, Adama; Shen Qu; Perdomo, German; Dongming Su; Dae Hyun Kim; Slusher, Sandra; Meseck, Marcia; Dong, H. Henry; Qu, Shen; Su, Dongming; Kim, Dae Hyun // Journal of Clinical Investigation;Jun2008, Vol. 118 Issue 6, p2347 

    Excessive production of triglyceride-rich VLDL is attributable to hypertriglyceridemia. VLDL production is facilitated by microsomal triglyceride transfer protein (MTP) in a rate-limiting step that is regulated by insulin. To characterize the underlying mechanism, we studied hepatic MTP...

  • Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. Babitt, Jodie L.; Huang, Franklin W.; Yin Xia; Sidis, Yisrael; Andrews, Nancy C.; Lin, Herbert Y.; Xia, Yin // Journal of Clinical Investigation;Jul2007, Vol. 117 Issue 7, p1933 

    Systemic iron balance is regulated by hepcidin, a peptide hormone secreted by the liver. By decreasing cell surface expression of the iron exporter ferroportin, hepcidin decreases iron absorption from the intestine and iron release from reticuloendothelial stores. Hepcidin excess has been...

  • Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. Zhe Jiang; Tao Deng; Jones, Robert; Huiqin Li; Herschkowitz, Jason I.; Liu, Jeff C.; Weigman, Victor J.; Ming-Sound Tsao; Lane, Timothy F.; Perou, Charles M.; Zacksenhaus, Eldad; Jiang, Zhe; Deng, Tao; Li, Huiqin; Tsao, Ming-Sound // Journal of Clinical Investigation;Sep2010, Vol. 120 Issue 9, p3296 

    Breast cancer is a highly heterogeneous disease, with several different subtypes being characterized by distinct histology, gene expression patterns, and genetic alterations. The tumor suppressor gene retinoblastoma 1 (RB1) is frequently lost in both luminal-B and triple-negative tumor (TNT;...

  • Breast cancer stem cells, cytokine networks, and the tumor microenvironment. Korkaya, Hasan; Suling Liu; Wicha, Max S.; Liu, Suling // Journal of Clinical Investigation;Oct2011, Vol. 121 Issue 10, p3804 

    Many tumors, including breast cancer, are maintained by a subpopulation of cells that display stem cell properties, mediate metastasis, and contribute to treatment resistance. These cancer stem cells (CSCs) are regulated by complex interactions with the components of the tumor microenvironment -...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics